KRAS and colorectal carcinoma: This knowledge sparked hypotheses regarding the rapid feedback reactivation of the EGFR-MAPK pathway in response to KRAS inhibition in CRC, similarly to what was already reported for BRAF V600E inhibitors [60,61].